Skip to Main Content
1-877-YALEMDS
SpecialistsFact SheetsDepartmentsClinical TrialsNewsPatient ToolsFor Medical Professionals
1-877-YALEMDS
  • Search
  • Clinical Trials
  • Roy S. Herbst

Clinical Trials

    • Cancer(4)
  • Lung Cancer

    Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer

    • Lung Cancer

      Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

      • Lung Cancer

        Phase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

        • Lung Cancer

          Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

          • About Us
          • Contact Us
          • Donate
          • Referring Doctors
          • Clinical Keywords

          333 Cedar St.

          New Haven, CT 06510

          • Yale School of Medicine
          • Yale University
          • Terms & Privacy Policies
          • Accessibility at YSM
          • Patient Rights
          • HIPAA at Yale
          • Non-discrimination Statement
          Copyright 2025 Yale Medicine